Amytrx Therapeutics
Dr. Shima Joshi is the Vice President of Regulatory Affairs at Amytrx and manages the company’s pharmaceutical drug substance quality control, assurance and compliance requirements. Shima has over 20 years of experience, including extensive regulatory affairs expertise supporting product development across all phases of clinical testing and registration. Dr. Joshi is an experienced executive, serial entrepreneur and co-founder of Star Biochemicals, acquired by Mallinckrodt; Peptisyntha, acquired by Solvay; and STAR Bio Solutions, a company specializing in peptide APIs. Dr. Joshi received her Ph.D. in Peptide Chemistry from Kobe Gakuin University in Japan.
This person is not in any offices
Amytrx Therapeutics
Amytrx Therapeutics is advancing a new class of peptide therapies to overcome inflammatory diseases—with a vision of providing transformative medicines to patients.